Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.0M
1M shares
52-week range
$1.13 – $16.68
2% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
881.33%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $249.0K | $0 | $0 | $0 |
| Cost of revenue | $143.0K | $157.0K | $0 | $200.1K | $0 | $0 | $0 |
| Gross profit | −$143.0K | −$157.0K | $0 | $48.9K | $0 | $0 | $0 |
| Gross margin | — | — | — | 19.6% | — | — | — |
| R&D | $454.6K | $527.3K | $1.1M | $4.2M | $5.7M | $3.5M | $3.0M |
| Operating income | −$1.6M | −$1.2M | −$3.2M | −$9.3M | −$10.3M | −$7.2M | −$7.0M |
| EBITDA | −$1.5M | −$1.0M | −$3.0M | −$9.0M | −$9.2M | −$6.7M | −$6.7M |
| Net income | −$757.7K | −$1.1M | −$3.7M | −$9.3M | −$10.0M | −$7.7M | −$6.8M |
| Net margin | — | — | — | -3733.1% | — | — | — |
| EPS (diluted) | -38.20 | -56.76 | -118.68 | -292.88 | -290.48 | -456.76 | -15.25 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-464.00 | $-464.00–$-464.00 | 1 |
| 2027 | $18M | $-32.00 | $-32.00–$-32.00 | 1 |
| 2028 | $33M | $400.00 | $400.00–$400.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
www.bluejaydx.comNo one on the platform currently holds BJDX.
No tracked institution reports a position in BJDX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-01-29 | 1-for-4reverse |
| 2024-11-18 | 1-for-50reverse |
| 2024-06-20 | 1-for-8reverse |
| 2023-07-24 | 1-for-20reverse |
No one on the platform has traded BJDX yet.
| $161160 |
| — |
| NKGNNKGen Biotech, Inc. Common Stock | $0.06 | +0.00% | $8M | — |
| TIVCTivic Health Systems, Inc. | $0.54 | -2.52% | $586042 | — |
Source: Financial Modeling Prep · peers by sector/industry
$BJDX You all saw what they they did to $INLF right? $4.55 back on June 16 and then it was 2 cents just 6 days later? That's what they are also doing here to BJDX. Seriously.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.